Quorum Review IRB, industry member in central IRB services, unveils today a Site Enrollment Service as part of their 2013 platform of ethics review services.
Quorum’s Site Enrollment Service allows customers to delegate the IRB startup component of clinical research for minimal cost. Quorum Review Site Support personnel will reach out to the research sites identified by the sponsor/CRO to support those sites through the submission process. The sponsor/CRO will receive on-going status updates.
As Quorum Review CEO Cami Gearhart, JD, explains, this service provides a new level of site management within the study start up process. “Site start-up that is quick and efficient is mission-critical for our customers. By leveraging the expertise of our site support team, we can help our customers streamline the collection of study start-up documentation.”
While the service is focused on the initial site submission phase to the IRB, clients have access to the service any time a new site is considered for participation in a central study. More information on the new Site Enrollment Service and all of Quorum’s ethics review services can be found at www.quorumreview.com.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Long-Term Analysis Shows Tafinlar Plus Mekinist Reduces Mortality Risk in Stage III Melanoma
November 11th 2024Phase III COMBI-AD trial final analysis shows that 12 months of adjuvant therapy with Tafinlar (dabrafenib) and Mekinist (trametinib) in patients with resected stage III melanoma significantly improved relapse-free survival and distant metastasis-free survival compared to placebo.